YOCHAI BIRNBAUM to Tetrazoles
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Tetrazoles.
Connection Strength
1.732
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
Score: 0.379
-
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
Score: 0.376
-
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011 Dec; 25(6):505-15.
Score: 0.354
-
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007 Oct; 21(5):321-30.
Score: 0.265
-
Cilostazol: a Review of Basic Mechanisms and Clinical Uses. Cardiovasc Drugs Ther. 2022 08; 36(4):777-792.
Score: 0.169
-
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
Score: 0.108
-
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y Acad Sci. 2010 Oct; 1207:76-82.
Score: 0.082